Aptiom Approval History
FDA Approved: Yes (First approved November 8, 2013)
Brand name: Aptiom
Generic name: eslicarbazepine acetate
Dosage form: Tablets
Previous Name: Stedesa
Company: Sunovion Pharmaceuticals Inc.
Treatment for: Epilepsy, Seizures
Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures in patients with epilepsy.
Development History and FDA Approval Process for Aptiom
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.